Janux Therapeutics’ Post

Interested in hearing the latest updates on the Nuvalent clinical trial focused on ALK-positive cancer? Nuvalent is hosting a conference call and live video webcast on October 13th at 8am EST. Learn more here: #nuvalent #cancer #oncology #alkpositive #alkpositivecancer

MacroGenics, Inc. has shared data from the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC). Early interim safety data from the Phase 2 TAMARACK study (NCT05551117), including comparison to retrospective analysis from a Phase 1 study (as submitted in an ASCO abstract that was not accepted), is included in the press release. Overall conclusions are: Preliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in men with mCRPC. The company plans to provide updated interim data, including safety and preliminary efficacy, by May 31. #mabs #adcs https://lnkd.in/eE57D7mu

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, according to data released ahead of ASCO, but four participants in the trial died. Patient deaths are not unheard of in early-stage testing. But these cases could give pause to other drug developers, as Johnson & Johnson is one of the first to report clinical data on a next-generation isotope that is theorized to be safer. It may also hamper how much Johnson & Johnson can increase the dose of JNJ-6420 in order to boost the response rate. What do you think about the radiopharmaceutical data? #radiopharmaceuticals #ASCO #ASCO2024 #pharma #cancer #oncology #drugdevelopment #clinicaltrials #radiation

Mythic Therapeutics, Inc. announced promising initial results from the Phase 1 KisMET-01 study of MYTX-011, a novel cMET-targeting ADC, in treating advanced or metastatic non-small cell lung cancer (NSCLC). The study, presented at the ASCO Annual Meeting, showed MYTX-011 was well-tolerated with no dose-limiting toxicity and demonstrated nearly dose-proportional pharmacokinetics. The study continues to assess safety, tolerability, and preliminary anti-tumor activity, with further efficacy data to be presented in the future. The findings offer hope for patients with diverse cMET expression levels. #HemiBio Brian Fiske https://lnkd.in/epvx2gPC

Finally, Merck acquired Harpoon therpaeutics. Harpoon Therapeutics has Tri-specific T cell Activating Construct (TriTAC®) platform and Harpoon’s lead candidate, HPN328, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand that is expressed at high levels in small cell lung cancer (SCLC) and neuroendocrine tumors (P1/2). https://lnkd.in/gQMcbSMe

#AntibodyDrugConjugates are a class of #anticancer therapeutics delivering highly cytotoxic molecules directly to #cancercells. However, second-generation ADCs are looking to reduce toxicity and improve the magnitude and duration of response in #solidtumors. https://lnkd.in/gWAXUrwX #cancer #oncology #AACR #CancerResearch #AACR2024 #AACR24

ICYMI, Convergent was recently mentioned in BioPharma Dive in an article focusing on how radiopharmaceuticals work, why they are the hot area of investment and the current radiotherapies in development. Read the full article by Ben Fidler here: https://bit.ly/3KKGox5 #radiopharmaceuticals #cancer

We continue to do what we said we would do, and make very good progress with the aim of developing off-the-shelf medicines that induce a personalized anti-tumor immune response. Many inflection points in the near future. #CandelTherapeutics #viral #immunotherapy #cancer #tumor #lungcancer #pancreaticcancer #prostatecancer #glioblastoma https://lnkd.in/ecaJQ-rG

eFFECTOR Therapeutics, Inc. said it will halt development of tomivosertib in #lungcancer after the MNK inhibitor failed to significantly improve survival. https://lnkd.in/d3cMqd4y #biotechnology #cancer #clinicalresearch #clinicaltrials #drugdevelopment #oncology #pharmaceuticals

📈 The data have spoken: Testing before treatment initiation is a crucial component in delivering better health outcomes for lung cancer patients. Researchers at the University of Pennsylvania found that non-small cell lung cancer patients who underwent molecular testing before starting first-line treatment lived nearly four times longer than those who didn’t. These results reinforce why we push for every patient at every stage to have to get biomarker testing: to ensure that they receive the most effective medicine for their unique disease. Explore the results in depth here: https://lnkd.in/e2bSHvb9 #LungCancer 🫁